Accinov to open a pharmaceutical site in Lyon-Gerland district
To support the production of biological drugs for clinical trials
The French Health Authority (ANSM) has granted Accinov, the Innovation Centre of Lyonbiopole, the authorisation to open a pharmaceutical site at its facilities in the Lyon-Gerland Biodistrict. This will allow Accinov to support companies hosted in the Centre in the manufacture of biological drugs for clinical trials.
The authorisation follows a successful inspection completed on the site by the French Agency.
Accinov will provide companies involved in drug development programmes with ready-to-use industrial facilities and pharmaceutical support services including quality assurance and batch release.
Lyonbiopole is the one-stop shop for healthcare innovation in Rhône-Alpes, France. It aims to support the emergence and development of innovative technologies, products and services in four main strategic areas of human medicine, veterinary medicine, in vitro diagnostics, medical devices and medical technologies. Focused on infectious diseases since its creation in 2005, Lyonbiopole is now supporting ambitious projects and companies in other fields such as cancer, nutrition, metabolic diseases and neurosciences.
In 2013, Lyonbiopole represented a community of 139 members: four world-class leaders as Lyonbiopole’s founders (Sanofi Pasteur, bioMérieux, Merial, BD); 19 Research Centres including three Hospital University Centres and almost 116 SMEs.
